Edward F. Mackey - 28 Feb 2022 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Reporting relationship: EVP, Operations
Issuer ticker: BSX
Reported as of: 28 Feb 2022
Net transaction value: -$47,880
SEC form: 4
Accepted by SEC: 02 Mar 2022, 15:27:35 UTC
Prior SEC filing: 24 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ Susan Thompson, Attorney-in-Fact

Key filing fact

Edward F. Mackey filed Form 4 for BOSTON SCIENTIFIC CORP (BSX) on 02 Mar 2022.

Key facts

This page summarizes Edward F. Mackey's Form 4 filing for BOSTON SCIENTIFIC CORP (BSX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Mar 2022, 15:27.

Change

Previous filing in this sequence was filed on 24 Feb 2022.
Current net transaction value: -$47,880.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BSX transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +2,444
Change %: +4.7%
Price: $0.000000
Shares after: 54,028
Date: 28 Feb 2022
Ownership: Direct
Footnotes: F1

BSX transaction

Common Stock

Tax liability

Transaction value: $47,880
Shares: -1,084
Change %: -2%
Price: $44.17
Shares after: 52,944
Date: 28 Feb 2022
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BSX transaction Derivative

Deferred Stock Units

Options Exercise

Transaction value: $0
Shares: -2,444
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 28 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,444
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

Footnote F2

Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.